Market Place
Sourcing Support
Dyadic To Present 2025 Financial Results, Host Conference Call
11 Mar 2026 //
GLOBENEWSWIRE
Dyadic, Fermbox Bio Boost Collaboration For Animal-Free Proteins
17 Dec 2025 //
GLOBENEWSWIRE
Dyadic Partners to Boost Recombinant Protein Output
15 Dec 2025 //
GLOBENEWSWIRE
Dyadic To Report Q3 2025 Financial Results On Nov 12, 2025
29 Oct 2025 //
GLOBENEWSWIRE
Dyadic Biosolutions Reveals Milestones And Recent Progress
06 Oct 2025 //
GLOBENEWSWIRE
Dyadic to Present at Investor Conferences and BPI East
04 Sep 2025 //
GLOBENEWSWIRE
Dyadic to Report Q2 2025 Financial Results on August 13
05 Aug 2025 //
GLOBENEWSWIRE
Dyadic International Prices Public Offering of 6,052,000 Shares
31 Jul 2025 //
GLOBENEWSWIRE
Dyadic International Proposes Public Offering of Stock
30 Jul 2025 //
GLOBENEWSWIRE
Dyadic International Rebrands to Dyadic Applied BioSolution
02 Jul 2025 //
BUSINESSWIRE
Dyadic to Report Q1 2025 Financial Results on May 14, 2025
01 May 2025 //
GLOBENEWSWIRE
Dyadic to Present at World Vaccine Congress | Washington
16 Apr 2025 //
GLOBENEWSWIRE
Dyadic to Attend Multiple Industry Events in March
06 Mar 2025 //
GLOBENEWSWIRE
Dyadic Provides Update & Attend 43rd J.P. Morgan Conference
06 Jan 2025 //
GLOBENEWSWIRE
Dyadic Receives $3M Grant for Monoclonal Antibodies for RSV
21 Nov 2024 //
GLOBENEWSWIRE
Dyadic Announces Q3 2024 Financial Results & Strategic Progress
12 Nov 2024 //
GLOBENEWSWIRE
Dyadic to Report Q3 2024 Financial Results on Nov 12, 2024
04 Nov 2024 //
GLOBENEWSWIRE
Dyadic Expands Global Presence At Key Industry Events
09 Oct 2024 //
GLOBENEWSWIRE
Dyadic Updates On Alternative Proteins Business
23 Sep 2024 //
GLOBENEWSWIRE
Dyadic Announces Q2 2024 Results And Recent Company Progress
13 Aug 2024 //
GLOBENEWSWIRE
Dyadic To Report Q2 2024 Results On August 13
30 Jul 2024 //
GLOBENEWSWIRE
Dyadic Announces Results from iPhase 1 Trial for Fungal-Based Vaccine Candidate
29 Nov 2023 //
GLOBENEWSWIRE
Dyadic™s C1 Platform Selected by the Vaccine and Immunotherapy Center
05 Oct 2023 //
GLOBENEWSWIRE
Dyadic Announces Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Dyadic Provides Phase 1 Trial Update for RBD Vaccine Candidate
24 Jul 2023 //
GLOBENEWSWIRE
Dyadic Announces Expanded Agreement to Develop Vaccines
12 Apr 2023 //
GLOBENEWSWIRE
Dyadic to Present at World Vaccine Congress Washington 2023
30 Mar 2023 //
GLOBENEWSWIRE
Dyadic Provides Phase 1 Trial Update for its DYAI-100 Vaccine Candidate
07 Mar 2023 //
GLOBENEWSWIRE
Dyadic Announces Initiation of Dosing of First-In-Human PI Trial for DYAI-100
24 Jan 2023 //
GLOBENEWSWIRE
